| Molecular biomarkers for contemporary therapies in hormone receptor-positive breast cancer A Freelander, LJ Brown, A Parker, D Segara, N Portman, B Lau, E Lim Genes 12 (2), 285, 2021 | 31 | 2021 |
| CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective FH Zhou, T Downton, A Freelander, J Hurwitz, CE Caldon, E Lim Frontiers in cell and developmental biology 11, 1148792, 2023 | 24 | 2023 |
| Type 1 nuclear receptor activity in breast cancer: Translating preclinical insights to the clinic S Kumar, A Freelander, E Lim Cancers 13 (19), 4972, 2021 | 13 | 2021 |
| Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer C Guarducci, A Nardone, D Russo, Z Nagy, C Heraud, A Grinshpun, ... Clinical Cancer Research 30 (9), 1889-1905, 2024 | 8 | 2024 |
| Abstract PD2-02: Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers A Freelander, G Laven-Law, L Eshraghi, KM Chia, M Pickering, A Yong, ... Cancer Research 82 (4_Supplement), PD2-02-PD2-02, 2022 | 4 | 2022 |
| Estrogen receptor positive breast cancer patient–derived xenograft models in translational research KM Chia, A Freelander, S Kumar, A Parker, D Segara, N Portman, E Lim Current Opinion in Endocrine and Metabolic Research 15, 31-36, 2020 | 2 | 2020 |
| Abstract P4-08-16: Selective Androgen Receptor Modulators in combination with CDK4/6 inhibitors demonstrate anti-cancer activity in preclinical treatment resistant ER+ AR+ … A Freelander, G laven-Law, L Eshraghi, N Geetha, P Somerville, ... Cancer Research 83 (5_Supplement), P4-08-16-P4-08-16, 2023 | | 2023 |
| Targeting clinical mechanisms of therapy resistance in ER+ breast cancer using an AR agonistic approach A Freelander UNSW Sydney, 2023 | | 2023 |
